Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Exp Neurol. 2019 Jul 9;320:113010. doi: 10.1016/j.expneurol.2019.113010

Figure 1.

Figure 1.

R-47 reverses CIPN in mice in an α7-dependent manner with no development of tolerance. A) Acute administration of R-47 at doses of 1, 5, and 10 mg/kg p.o. reverses mechanical hypersensitivity in paclitaxel-treated mice. *P < 0.0001 vs distilled water (0 mg/kg); #P < 0.0001 vs R-47 (1 mg/kg); $P < 0.0001 vs R-47 (5 mg/kg). B) Administration of MLA, an α7 nAChR antagonist, at a dose of 10 mg/kg s.c. 10 minutes before R-47 (10 mg/kg, p.o.) blocks the antinociceptive effect of R-47 in paclitaxel-treated mice. *P < 0.0001 Veh-R-47 at 180 min vs 0 min; #P < 0.0001 MLA-R-47 vs Veh-R-47 at 180 min. C) Administration of R-47 at a dose of 10 mg/kg p.o. for four days and on day 5 (challenge day) shows the antinociceptive effect in paclitaxel-treated mice. *P < 0.0001 Veh-R-47 at 180 min vs 0 min; #P < 0.0001 R-47-R-47 at 180 vs R-47-R-47 at 0 min. BL, Baseline; Veh, vehicle; Pac, paclitaxel; MLA, methyllycaconitine; n = 8 per group; data expressed as mean ± SEM.